Sir,Selective serotonin reuptake inhibitors (SSRI) are used worldwide for various neuropsychiatric disorders and other medical diagnoses such as chronic pain and irritable bowel syndrome with few drug-related complications for more than 30 years. It is well known that regular blood tests are required for SSRI-related common side-effects such as increased bleeding and increase in liver enzymes. However, there might be other unrecognized side-effects yet to be reported. We have previously reported an increase in carcinoembryonic antigen (CEA) in two patients on paroxetine and escitalopram.[12] Here, we report the third case with mildly elevated CA 15-3 and CEA tumor markers related to prolonged sertraline use.
Case
74-year-old female nonsmoker patient had symptoms of distress, reluctance to go outside, social isolation, insomnia, anorexia, inability to do daily chores, and was diagnosed with DSM-5 Major Depressive Disorder. She had diabetes mellitus that was well-controlled with metformin 2000 mg/day, and she had no personal or family history of malignancy. She was already on sertraline 100 mg/day and melatonin 3 mg/day when she was examined. She had been using sertraline in the range of 50–100 mg/day during the last 20 years. Biochemical workup for the presenting symptoms' differential etiology yielded a minimal increase in tumor markers CA 15-3 = 23,01 (0–23) and CEA = 7,64 (0–5). The sedimentation rate was 28, which is typical for her age group (<25). Further detailed workup for any malignancy was negative. Therefore, we associated the mild increase in CA 15-3 and CEA with prolonged use of sertraline regarding our previous experience with escitalopram and paroxetine. The tumor markers returned to normal levels as sertraline was decreased gradually to 37.5 mg/day with the addition of mirtazapine 7.5 mg/day and medazepam 10 mg/day. She remains symptom-free after 3 months of treatment.The prevention of bone fractures is a priority for the elderly because the neuropsychiatric well-being of old-aged people deteriorates after a bone fracture.[3] In a study, increased CEA levels were associated with bone fractures.[4] SSRIs are reported to reduce bone formation, possibly through their effects on the gut-mediated pathway.[5] It is debatable whether this increased bone fracture rate is also related to SSRI-associated CEA increase. Even though the exact mechanism of the increase in tumor markers is not precise in our patients, it might be suggested that SSRI use is asked in all patients with increased CEA before proceeding with further detailed malignancy investigations.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initial s will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.